David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Can you rechallenge with Enfortumab Vedotin after progression?
New real-world data from Michal Sternschuss at ASCO 2026 says: in some yes – promising in patients with prior EV benefit and EV-free interval more than 6 months.
55 patients, ORR 25%, median OS 15.2 months. Abstract 547088, Poster A57.”
Other articles featuring Dr. Aggen on OncoDaily.